Pharmacoanalytical assays of Erwinia asparaginase (Erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: Simulations of Erwinase population PK-PD models

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2561-2572

  Avramis, Vassilios I ^a,e   Martín Aragón, Sagrario ^a,b   Avramis, Earl V ^a,c   Asselin, Barbara L ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

ALL; Erwinia asparaginase; Non linear mixed effects model (NONMEM); Pharmacodynamics; Pharmacokinetics; Treatment outcome

Indexed keywords

ASPARAGINASE; ASPARAGINE; ENZYME ANTIBODY; GLUTAMINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANALYTIC METHOD; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ASSAY; ERWINIA; HUMAN; ONCOLOGY; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS; TREATMENT DURATION; VALIDATION PROCESS;

ANTIBODIES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERWINIA; ESCHERICHIA COLI; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; REPRODUCIBILITY OF RESULTS;

EID: 34547811078     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Broome JD: Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serumin relation to those of the antilymphoma substance. J Exptl Med 118: 99-120, 1963.
2. Schwartz JH, Reeves JY and Broome JD: Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci 56: 1516-1519, 1966.
3. Wade HE, Elsworth R, Herbert D et a: A new L-asparaginase with anti-tumor activity. Lancet 2: 776-777, 1968.
4. Oettgen HF, Old LJ, Boyse HA et al: Inhibition of leukemias in man by L-asparaginase. Cancer Res 27: 2619-2631, 1967.
5. Chabner BA and Loo TL: Enzyme therapy: L-asparaginase. In: Cancer Chemotherapy and Biotherapy, Principles and Practice. Second edition. Chabner BA and Longo DL (eds.). Philadelphia, PA: Lippincott-Raven Publishers, pp. 485-492, 1996.
6. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM and Gaynon PS: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338(23): 1663-1671, 1998.
7. Ertel IJ, Nesbit ME, Hammond D, Weiner J and Sather H: Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res 39(10): 3893-3896, 1979.
8. Capizzi RL and Holcenberg, JS: Asparaginase. In: Cancer Medicine, 3rd edition. Ed. James F. Holand, Lea and Febiger (eds.). Philadelphia, pp. 796-805, 1993.
9. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE and Cohen HJ: Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11(9): 1780-1786, 1993.
10. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS and Stork L: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99(6): 1986-1994, 2002.
11. Boos J: Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Ther 35(3): 96-98, 1997.
12. Avramis VI and Panosyan EH: Pharmacokinetic/ pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4): 367-393, 2005.
13. Pinheiro JP and Boos J: The best way to use asparaginase in childhood acute lymphatic leukaemia - still to be defined? Br J Haematol 125(2): 117-127, 2004.
14. Graham ML: Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 55(10): 1293-1302, 2003.
15. Pui CH and Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2): 166-178, 2006.
16. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE and Avramis VI: Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 26(4): 217-226, 2004.
17. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA and Avramis VI: Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 18(2): 107-112, 2004.
18. Reinert RB, Oberle LM, Wek SA et al: Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 281(42): 31222-31233, 2006.
19. Cheung NK, Chau IY and Coccia PF: Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 8(2): 99-104, 1986.
20. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH and Relling MV: Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12(10): 1527-1533, 1998.
21. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP and Avramis VI: Pharmacodynamics and Safety of Intravenous Pegylated L-Asparaginase During Remission Induction in Adult Newly Diagnosed Acute Lymphoblastic Leukemia. BLOOD 109: 2744-2750, 2007.
22. Tiwari PN, Zielinski M, Quinn JJ, Siegel SE, Gaynon PS, Wakamatsu P, Seibel NL and Avramis VI: Assessment of anti-asparaginase (ASNase) antibodies (Ab) and ASNase activity after suspected clinical allergy. Blood 108(11): 532a, (Abstr # 1878), 2006.
23. Panosyan EH, Grigorian RS, Avramis IA, Jaques JD, Seibel NL, Ettinger LJ, Gaynon PS, Siegel SE, Fingert HJ and Avramis VI: Asparaginase (ASNase) activity, amino acid serum concentrations and clinical outcome in pediatric patients with higher risk acute lyphoblastic leukemia (HR ALL): A report from CCG-1961. Blood 102(11): p378a, Abstr. #1374, 2003.
24. Lavi LE, Holcenberg JS, Cole DE and Jolivet J: Sensitive analysis of asparagine and glutamine in physiological fluids and cells by precolumn derivatization with phenylisothiocyanate and reversed-phase high-performance liquid chromatography. J Chromatogr 377: 155-163, 1986.
25. Avramis VI and Spence SA: Clinical pharmacology of asparaginases - a review of the US clinical trials: asparaginase population pharmacokinetic and pharmacodynamic (PPK-PPD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 29(4): 239-247, 2007.